K-252A

K-252A

SCHEMBL15575821

COC(=O)C1(O)CC2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 9/20 1.00
▸ PRKCQ Q04759 6/20 1.00
▸ KDR P35968 6/20 1.00
▸ MAP3K11 Q16584 6/20 1.00
▸ MAP3K9 P80192 5/20 1.00
▸ PRKD3 O94806 4/20 1.00
▸ PRKCG P05129 4/20 1.00
▸ PRKCB P05771 4/20 1.00
▸ PRKCA P17252 4/20 1.00
▸ PRKCH P24723 4/20 1.00
▸ PRKCI P41743 4/20 1.00
▸ PRKCE Q02156 4/20 1.00
▸ PRKCZ Q05513 4/20 1.00
▸ PRKCD Q05655 4/20 1.00
▸ PRKD1 Q15139 4/20 1.00
▸ MAP3K10 Q02779 4/20 1.00
▸ MYLK Q15746 3/20 1.00
▸ CDK4 P11802 2/20 1.00
▸ CDK2 P24941 2/20 1.00
▸ CAMKK2 Q96RR4 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
K-252A SCHEMBL29434956 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL31181849 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL29355962 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL32665760 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL13993461 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL13787898 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL24112155 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL13485248 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL968886 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL29660621 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4567102-A1 METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AVIAN EMBRYONIC CELLS Suprême (FR) 2025-06-11 — — EP disclosed
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 — — US disclosed
WO-2023039578-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION (US) 2023-03-16 — — WO disclosed
CN-110468051-B K252A fermentation medium and preparation method thereof 海正药业(杭州)有限公司 2022-08-23 — — CN disclosed
US-20210322439-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH RTK MUTANT CELLS IGNYTA, INC. (US) 2021-10-21 — — US disclosed
CN-110468051-A A kind of K252A fermentation medium and preparation method thereof HISUN PHARMACEUTICAL HANGZHOU CO LTD 2019-11-19 — — CN disclosed
US-10094834-B2 Method of selecting individualized brain cancer therapy TURUN YLIOPISTO (FI) 2018-10-09 — — US disclosed
US-20180177792-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH RTK MUTANT CELLS IGNYTA, INC. (US) 2018-06-28 — — US disclosed
CN-104755936-B The method of the personalized cancer of the brain therapy of selection 图尔库大学 2018-04-27 — — CN disclosed
US-9918989-B2 Combination therapies for malaria THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-03-20 — — US disclosed
CN-105727296-A Medicine for killing tumor cells and stem cells thereof and preparation method thereof 昆明医科大学 2016-07-06 — — CN disclosed
US-20160151380-A1 THERAPIES FOR DISEASES CAUSED BY ARTHROPOD-BORNE PARASITES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-06-02 — — US disclosed
US-20160151379-A1 COMBINATION THERAPIES FOR MALARIA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-06-02 — — US disclosed
EP-2723450-B1 COMBINATION THERAPY TURUN YLIOPISTO (FI) 2016-05-18 — — EP disclosed
US-20150204877-A1 METHOD OF SELECTING INDIVIDUALIZED BRAIN CANCER THERAPY TURUN YLIOPISTO (FI) 2015-07-23 — — US disclosed
EP-2890986-A1 METHOD OF SELECTING INDIVIDUALIZED BRAIN CANCER THERAPY Turun Yliopisto (FI) 2015-07-08 — — EP disclosed
CN-104755936-A Method of selecting individualized brain cancer therapy TURUN YLIOPISTO 2015-07-01 — — CN disclosed
CN-104619845-A Combination therapy iii TURUN YLIOPISTO 2015-05-13 — — CN disclosed
WO-2015006752-A1 COMBINATION THERAPIES FOR MALARIA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-01-15 — — WO disclosed
WO-2014033367-A1 METHOD OF SELECTING INDIVIDUALIZED BRAIN CANCER THERAPY TURUN YLIOPISTO (FI) 2014-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER TP53, CD4, MCL1 NTRK1 4199/4885PRKCQ 1247/4885KDR 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback